Janssen pulls plug on Alzheimer’s candidate
Safety concerns have prompted Janssen to pull the plug on a development programme testing the BACE inhibitor atabecestat for Alzheimer’s disease.
Read More
Tag: verubecestat
MSD’s verubecestat fails again in Alzheimer’s trial
The Alzheimer’s disease research field has taken yet another hit with the failure of MSD’s verubecestat in a late-stage trial.
Read More
Merck pulls plug on late-stage Alzheimer’s trial
Merck & Co has terminated a Phase II/III trial testing its investigational medicine verubecestat in patients with mild to moderate Alzheimer’s disease.
Read More
Merck drug shows promise in Alzheimer’s disease
Merck & Co’s BACE1 inhibitor verubecestat has shown promise in a Phase I trial assessing its potential in Alzheimer’s disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
